Similar articles

• Immune response and vaccine efficacy.

  Afzal MA, Minor PD. Afzal MA, et al. Vaccine. 1999 Apr 9;17(15-16):1813. doi: 10.1016/s0264-410x(98)00459-9. Vaccine. 1999. PMID: 10217577 No abstract available.
• Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.

  Cilla G, Peña B, Marimón JM, Pérez-Trallero E. Cilla G, et al. Vaccine. 1996 Apr;14(6):492-4. doi: 10.1016/0264-410x(95)00234-r. Vaccine. 1996. PMID: 8782345
• [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].

  Samoĭlovich EO, Kapustik LA, Fel'dman EV, Ermolovich MA, Svirchevskaia EIu, Titov LP, Zakharenko DF, Belova EIu, Chernovetskiĭ MA, Korostik TS. Samoĭlovich EO, et al. Zh Mikrobiol Epidemiol Immunobiol. 1998 Jul-Aug;(4):36-40. Zh Mikrobiol Epidemiol Immunobiol. 1998. PMID: 9783398 Russian.
• Vaccine-induced antibodies by commercial test kits, the case of the Rubini mumps and the Edmonston-Zagreb measles vaccine strains.

  Poltera AA, Herzog C. Poltera AA, et al. Vaccine. 2000 Oct 15;19(4-5):396-8. doi: 10.1016/s0264-410x(00)00200-0. Vaccine. 2000. PMID: 11203403 Review. No abstract available.
• Waning immunity and re-emergence of measles and mumps in the vaccine era.

  Yang L, Grenfell BT, Mina MJ. Yang L, et al. Curr Opin Virol. 2020 Feb;40:48-54. doi: 10.1016/j.coviro.2020.05.009. Epub 2020 Jul 4. Curr Opin Virol. 2020. PMID: 32634672 Review.